Bayer Aktiengesellschaft (BAYRY)
OTCMKTS
· Delayed Price · Currency is USD
7.51
-0.02 (-0.27%)
Jun 6, 2025, 10:50 AM EDT
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 13.74B EUR in the quarter ending March 31, 2025, a decrease of -0.20%. This brings the company's revenue in the last twelve months to 46.58B, down -0.92% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
46.58B EUR
Revenue Growth
-0.92%
P/S Ratio
0.59
Revenue / Employee
514.19K EUR
Employees
90,587
Market Cap
29.73B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
Bayer Aktiengesellschaft News
- 23 hours ago - Bayer raised to Buy at Goldman after hitting bottom of negative earnings revision cycle - Seeking Alpha
- 1 day ago - Bayer Crop Science delegation visits ISARC - The Times of India
- 2 days ago - Bayer subsidiary gains worldwide rights to develop cancer asset VVD-214 - Seeking Alpha
- 2 days ago - Bayer gets FDA nod for Nubeqa in advanced prostate cancer - Seeking Alpha
- 2 days ago - Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor - Business Wire
- 3 days ago - Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress - Business Wire
- 9 days ago - Bayer says new lung cancer therapy granted FDA priority review - Seeking Alpha
- 14 days ago - Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea - Seeking Alpha